A PK-PD Study of PSN821 in Type 2 Diabetes Patients (T2DM)

Summary

The purpose of this study is to investigate the pharmacokinetics and pharmacodynamics of PSN821 in patients with type 2 diabetes. Subjects will be assessed for beta-cell function using a hyperglycaemic clamp before the start of treatment and at the end of a 12 week treatment period as the primary endpoint. HbA1c, fasting plasma glucose and body weight are secondary endpoints.

Timeline

Start

2011-05

Primary completion

2012-01

Completion

2012-05

Drugs

Indications